Bridgeway Capital Management, LLC Zynerba Pharmaceuticals, Inc. Transaction History

Bridgeway Capital Management, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.4 - $0.67 $20,000 - $33,500	-50,000 Reduced 43.14%	65,900 $28,000
Q3 2022 Nov 14, 2022	SELL	$0.87 - $1.36 $43,500 - $68,000	-50,000 Reduced 30.14%	115,900 $85,000
Q2 2022 Aug 15, 2022	SELL	$0.86 - $2.06 $8,600 - $20,600	-10,000 Reduced 5.69%	165,900 $189,000
Q1 2022 May 16, 2022	SELL	$1.83 - $3.02 $39,711 - $65,534	-21,700 Reduced 10.98%	175,900 $361,000
Q4 2021 Feb 14, 2022	SELL	$2.88 - $4.3 $144,000 - $215,000	-50,000 Reduced 20.19%	197,600 $569,000
Q3 2021 Nov 15, 2021	BUY	$3.72 - $5.35 $364,560 - $524,300	98,000 Added 65.51%	247,600 $1.05 Million
Q2 2021 Aug 16, 2021	BUY	$3.83 - $5.98 $46,726 - $72,956	12,200 Added 8.88%	149,600 $791,000
Q4 2020 Feb 16, 2021	BUY	$3.27 - $4.64 $112,815 - $160,080	34,500 Added 33.53%	137,400 $453,000
Q3 2020 Nov 16, 2020	SELL	$3.23 - $4.3 $52,649 - $70,090	-16,300 Reduced 13.67%	102,900 $341,000
Q2 2020 Aug 14, 2020	BUY	$3.31 - $6.54 $249,905 - $493,770	75,500 Added 172.77%	119,200 $402,000
Q1 2020 May 15, 2020	SELL	$2.9 - $6.16 $145,000 - $308,000	-50,000 Reduced 53.36%	43,700 $167,000
Q4 2019 Feb 14, 2020	BUY	$5.61 - $8.57 $74,052 - $113,124	13,200 Added 16.4%	93,700 $566,000
Q1 2019 May 15, 2019	BUY	$3.6 - $6.22 $90,000 - $155,500	25,000 Added 45.05%	80,500 $436,000
Q2 2018 Aug 14, 2018	BUY	$7.98 - $12.39 $51,870 - $80,535	6,500 Added 13.27%	55,500 $541,000
Q3 2017 Nov 14, 2017	BUY	$5.73 - $9.44 $280,770 - $462,560	49,000	49,000 $410,000

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.